Kornimate/medical-research-clean huggingface dataset:
feasibility of whole-body drumming classes for people with parkinson's disease

Conditions: Parkinson Disease

Summary: people with parkinson's disease (pd) experience difficulty with gait, postural instability, and lack of movement coordination and rhythmic timing. non-motor functions affected by pd include time perception, feelings of apathy, depression, decreased self-efficacy, and decrease self-reported quality of life. there is currently a lack of information on how a therapeutic drumming class that uses whole-body large-amplitude movements to music would impact these motor and non-motor impairments in individuals with pd. the primary purpose of this study is to assess the feasibility of a 10-week whole-body drumming class to music specifically selected for its rhythmic structure, and effects on movement rhythm and time perception in individuals with pd. the secondary purpose is to assess the effects of the drumming class on apathy, depression, self-efficacy and health-related quality of life. participants will be included if they have a diagnosis of pd and are able to move for an hour with rests, either standing or seated. participants are tested before and after the class series and one month following.


Eligibility criteria:
inclusion criteria: * diagnosed with pd * independent walking short community and household distances with or without assistive device * able to participate in a 1-hour class once a week for ten weeks exclusion criteria: * change of parkinson's medication or deep brain stimulation parameters within 2 weeks prior to or during the study * inability to grasp 2-inch diameter "drum sticks" * any conditions with contraindications to lift upper extremities overhead * any medical restrictions to exercise
journey ii bi-cruciate stabilized (bcs) total knee system retrospective study

Conditions: Total Knee Arthroplasty

Summary: the objective of this study is to estimate the safety and performance of journey ii bcs tks.

the objective of this study is to estimate the safety and performance of journey ii bcs tks. specifically, the study will establish revision rate, treatment- and device-related complications, and clinical outcomes in a large sample of subjects who received the study device. subjects are screened consecutively, beginning at the earliest date of implantation at each investigative site. further, reasons for revision will be collected and analyzed. an analysis will be performed to identify characteristics (patient, surgeon and surgical) associated with an increased risk for revision. finally, clinical, functional and quality of life outcomes will be analyzed to the extent data is available, given the retrospective study design.

Eligibility criteria:
inclusion criteria: * subject received primary uni- or bi-lateral total knee arthroplasty with the journey ii bcs total knee system for approved indication * the tka occurred at least 12 weeks prior to enrollment * subject records contain patient reported outcome data obtained ≤3 months prior to as well as ≥6 months post-enrollment. exclusion criteria: * subject received the journey ii bcs total knee system on the affected knee as a revision for a previously failed total or unicondylar knee arthroplasty

Keywords: rheumatoid arthritis post-traumatic arthritis osteoarthritis degenerative arthritis failed osteotomy
cryobiopsy versus forceps biopsy for pulmonary lesions

Conditions: Solitary Pulmonary Nodule; Multiple Pulmonary Nodules

Summary: purpose: patients with peripheral lung nodules require evaluation for lung cancer. our aim is to assess the diagnostic yield of a new technique, transbronchial cryobiopsies, in patients at risk for lung cancer. target population: patients referred for bronchoscopy and lung biopsies as a part of their work up for peripheral lung lesions. procedures: patients enrolled will have forceps transbronchial biopsies followed by transbronchial cryobiopsies for their lung lesion during bronchoscopy.


Eligibility criteria:
inclusion criteria: 1. age \>/= 18 2. at least one peripheral lung lesion \>8mm documented on ct scan referred for diagnostic bronchoscopy 3. subject is able to undergo informed consent exclusion criteria: 1. coagulopathy (platelet count \ 1.5) detected on blood testing done within 6 weeks of the procedural visit 2. lesion associated with a prominent vessel evident on ct scan 3. pure ground glass lesion 4. fibrotic interstitial lung abnormalities on chest ct 5. bullous emphysema in region of nodule 6. supplemental oxygen utilization at baseline 7. bmi \> 40 8. end stage renal disease
rdd1609 as a treatment for idiopathic pruritus ani

Conditions: Idiopathic Pruritus Ani

Summary: this is a double-blind, randomized, placebo-controlled, crossover trial, to test the hypothesis that rdd1609 is effective in treating idiopathic pruritus ani.

this is a phase 2a randomized double-blinded placebo-controlled cross-over design study in patients with idiopathic pruritus ani. 24 patients, male and females, aged 18 -65 with severe idiopathic pruritus ani (vas score above 60), will be randomized to this study. patients that meet all inclusion criteria and do not have exclusion criteria at randomization visit will be randomly assigned to one of the two treatment groups: group 1 will receive 3 weeks of rdd1609 for 3 weeks, followed by 3 weeks of treatment with placebo. group 2 will receive 3 weeks of treatment with placebo followed by 3 weeks of treatment with rdd1609.

Eligibility criteria:
inclusion criteria: 1. an institutional review board (irb) approved informed consent is signed and dated prior to any study-related activities. 2. male and female patients, age 18 - 65 years with idiopathic pa. 3. screening vas for itching of 60 mm and above. 4. female subjects of child-bearing potential must have a negative urine pregnancy test. females of childbearing potential must practice a highly effective method of pregnancy prevention (defined as \ = 12 months of spontaneous amenorrhea) or \ 40 miu/ml. 5. subject has normal (or abnormal and clinically insignificant) laboratory values at screening. 6. subject has the ability to understand the requirements of the study and a willingness to comply with all study procedures. 7. subject has not used and agrees to abstain from taking any prescription or non-prescription medications, cosmetics, including herbal and dietary supplements (such as st. john's wort) within 7 days prior to the first dose of study medication (unless authorized by the investigator and medical monitor). exclusion criteria: 1. known hypersensitivity to rdd1609. 2. known hypersensitivity to mebendazole. 3. previously treated with methylene blue for pruritus ani. 4. randomization vas for itching that is \<25 mm than the screening vas. 5. anorectal conditions such as malignant tumors of the anus and rectum, inflammatory bowel disease, fistulain- ano, fissure-in-ano, incontinence, condylomata, and second- and third-degree hemorrhoids and any other anorectal conditions that requires medicinal treatment. 6. patients who had previous major proctological surgery. 7. generalized skin disorders. 8. active psychiatric disorders. 9. diabetes mellitus all types. 10. known to be hiv positive. 11. current or within the last 4 weeks steroid or pregabalin or gabapentin or antihistamine systemic or local treatment.
anticoagulation profile in pregnant women treated with three times a day of low molecular weight heparin (lmwh)

Conditions: Pregnancy, High Risk; Anticoagulants

Summary: pregnancy is associated with a increased risk of developing blood clots. there is nearly a 5 times greater risk of developing a blood clot in pregnancy. lovenox is a medication that helps to prevent the body from developing clots. it is safe to use in pregnancy. previous studies have demonstrated that despite recommendation of lovenox, to prevent blood clots, the majority of patient's (70 to 90%) did not receive adequate levels of lovenox at times throughout the day, which likely increases the risk of developing clots. the increase in blood volume and increase in kidney function that occurs in pregnancy may contribute to the inadequate levels. currently the recommendation for pregnant and nonpregnant patients requiring lovenox, is to calculate the daily dose of lovenox and split the dose, giving half in the morning and the other half in the evening. this research study proposes that due to changes in the body during pregnancy that the daily lovenox dosing be split into three times a day to achieve more consistent levels of lovenox than twice a day in pregnant women.


Eligibility criteria:
inclusion criteria: * nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy. * participants must be age 18 or older. exclusion criteria: * women with multiples. * women less than age 18 * history of heparin induced thrombocytopenia (hit) * allergy to enoxaparin
respiratory motion related ablation gap and clinical outcome after catheter ablation for atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this is the evaluation which is associated with apnea symptom, one of the recurrence factors, after af ablation to patients who diagnosed af. this is the evaluation which is associated with excessive respiration exercise during af ablation to patients who diagnosed af. this is the evaluation which is associated with excessive respiration exercise to make a gap during af ablation to patients who diagnosed af.


Eligibility criteria:
inclusion criteria: 1. age 20\~80 2. left atrium size \<55mm exclusion criteria: 1. permeant af which is uncontrolled by cardioverting 2. valvular af (mitral stenosis\> grade 2, mitral valvuloplasty) 3. structural heart disease which is necessary operation to be healed. 4. the patients who had history of ablation or maze operation 5. the patients who have abnormal respiration by spinal or chest modification. 6. accompany severe disease in present 7. under age \<20

Keywords: atrial fibrillation, sleep apnea
understanding treatment adherence among individuals with rapid cycling bipolar disorder

Conditions: Bipolar Disorder

Summary: this study will examine how various factors, such as psychiatric symptoms, gender, quality of life, and attitudes toward medication, affect treatment adherence in individuals with rapid cycling bipolar disorder.

bipolar disorder (bpd), also known as manic-depressive illness, is a disorder that causes frequent shifts in an individual's mood, energy, and ability to function. an individual with bpd may go through periods of mania, which are characterized by increased energy, irritability, and an excessively "high" euphoric mood. the manic periods are followed by periods of depression, which are characterized by decreased energy, feelings of hopelessness, and anxiety. rapid cycling bipolar disorder (rcbpd) is a type of bpd in which the individual experiences four or more episodes of mania and depression per year. the rapid shift between the manic and depressive episodes makes it imperative that individuals with rcbpd strictly manage their illness with medication. many bpd medications have been developed recently; however, there are still many individuals who do not respond well to medication treatment. research has shown that the way individuals experience illness has an effect on their response to medication. the purpose of this study is to gain insight into how individuals with rcbpd perceive and respond to medication treatment. factors such as gender, degree of social support, drug and alcohol usage, and attitudes towards medication will be evaluated to understand how they affect medication and treatment adherence. this study will consist of 1 visit, which will last approximately 2 and ½ hours and will include an anthropological interview and numerous standardized psychological questionnaires. the interview and questionnaires will assess participants' attitudes toward bpd treatment; psychiatric illness severity, including symptoms of mania and depression; expectations regarding recovery, stigma, and quality of life; and medication adherence.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of rapid cycling variant of bipolar disorder type i; diagnosed 2 to 20 years prior to study entry * has experienced an index depressive episode * received treatment with medication to stabilize mood for at least 6 months prior to study entry * lives in the northeast ohio area and is a patient at either northeast ohio health services or the mood disorders clinic at university hospitals of cleveland exclusion criteria: * unable/unwilling to participate in psychiatric interviews

Keywords: depression, bipolar manic-depressive psychosis
a clinical trial for inactivated vaccine(vero cell) against ev71 in chinese healthy young adults and children

Conditions: Hand, Foot and Mouth Disease

Summary: hand, foot, and mouth disease (hfmd) is a common viral illness in infants and children caused by viruses that belong to the enterovirus genus of the picornavirus family. although most hfmd cases do not result in serious complications, outbreaks of hfmd caused by enterovirus 71 (ev71) can present with a high rate of neurological complications, including meningoencephalitis, pulmonary complications, and can even cause infant death. hfmd caused by ev71 has become a major emerging infectious disease in asia and the highly pathogenic potential of ev71 clearly requires the attention of world medical community. the development of vaccine against ev71 is active and ongoing in asian countries now. several studies have examined the effectiveness of inactivated viral vaccines against ev71 in animal model. a wide range of experimental ev71 vaccine approaches have been studied including heat-inactivated or formaldehyde-inactivated virion, ev71 virus-like particles (vlp) , vp1 recombinant protein ,vp1 dna vaccine , vp1 peptide-based vaccine targeting the neutralizing domain, bacterial or viral vector expressing vp1, and a vero cell-adapted live attenuated virus. furthermore, neutralizing antibodies against ev71 have been suggested as one of the most important factors in prevention of the severe ev71 infection. recently, an inactivated vaccine(vero cell) against ev71 has been licensed by sfda in china, this clinical trial phase ia is armed to evaluate safety and tolerance in chinese healthy adults and children.


Eligibility criteria:
inclusion criteria: * healthy subjects aged from 5 to 22 years old as established by medical history and clinical examination * the subjects or their guardians are able to understand and sign the informed consent * had never received the vaccine against ev71 * subjects who can and will comply with the requirements of the protocol exclusion criteria: * subject that has a medical history of hfmd * subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine * family history of seizures or progressive neurological disease * family history of congenital or hereditary immunodeficiency * women of pregnancy, lactation or about to be pregnant in 60 days * autoimmune disease or immunodeficiency * bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with im injections or blood draws * any prior administration of administration of immunoglobulins

Keywords: vaccines adverse reaction
utilization of aspirin for prevention of pre-eclampsia in nigeria: a explanatory sequential mixed methods study

Conditions: Hypertensive Disorders of Pregnancy

Summary: the goal of this study is to evaluate the use of aspirin for the prevention of preeclampsia among moderate -to- high-risk pregnant women in tertiary care hospitals in nigeria followed by a qualitative study to evaluate the barriers and facilitators of aspirin use in prenatal care for the prevention of preeclampsia in nigeria. the main question\[s\] it aims to answer are: 1. is aspirin used for the prevention of preeclampsia among pregnant women in nigeria? 2. what factors promote or prevent the utilization of aspirin for preeclampsia prevention among pregnant women in nigeria.

nigeria has the highest burden of maternal mortality worldwide accounting for over 1 in 4 of global maternal deaths. in a 2022 nationwide analysis of maternal outcomes in 76,563 deliveries across referral-level hospitals in nigeria, hypertensive disorders of pregnancy (hdp) including preeclampsia accounted for 32% of maternal deaths. studies have linked the pathophysiology of preeclampsia to peripartum cardiomyopathy (ppcm) which is prevalent in nigeria.5,6 patients with ppcm were 4 times as likely to have preeclampsia that patients without ppcm. among known evidence-based interventions for hdp, aspirin prophylaxis stands out as among the most highly effective in preeclampsia prevention. a comprehensive understanding of utilization patterns, or lack thereof, as well as the identification of barriers and facilitators, can inform implementation studies aimed at increasing adoption of this highly effective and cost-effective intervention. aims: 1. to conduct a multisite cross-sectional study to evaluate the utilization of aspirin use for the prevention of preeclampsia amongst moderate- to high-risk pregnant women in tertiary care hospitals in nigeria. we hypothesize that there is underutilization of aspirin for the prevention of preeclampsia amongst pregnant women at moderate- to high-risk of preeclampsia in nigeria. 2. to conduct a qualitative research study to evaluate facilitators and barriers to aspirin use in prenatal care for prevention of preeclampsia in nigeria. we hypothesize that there is underutilization of aspirin for the prevention of preeclampsia amongst pregnant women at moderate- to high- risk of preeclampsia in nigeria.

Eligibility criteria:
inclusion criteria: * adult pregnant woman \> 18 years old / emancipated pregnant minors (\<18years), according to the stipulations of the nigerian national health research ethics committee (nrhec) * \>12 weeks' gestation attending antenatal care clinics on 2nd or subsequent visit * those presenting to the labor and delivery room. exclusion criteria: * unable to provide consent
impact of screen size on colorectal adenoma detection

Conditions: Colon Polyp; Colon Adenoma; Colorectal Neoplasms

Summary: the purpose of this study is to assess whether the use of large screen during colonoscopy will increase adenoma detection rate.

colorectal cancer is the 3rd most common cancer in the world. recently in hong kong it has surpassed lung cancer to be the most common cancer. hence it is essential not only to have up-to-date surgical and oncological treatment but also a need an effective preventative strategy. in the past few decades, removal of pre-malignant colonic lesions such as adenomas have been shown to prevent development of colorectal cancers. colonoscopy is currently the only technique which can perform both detection and treatment during the same procedure. however, concerns have been raised about the effectiveness of colonoscopy in the prevention of crc after several studies reported unexpected high incidence rates of interval carcinomas (ic), especially in the proximal colon. most ics are suspected to arise from missed colon lesions during colonoscopy. factors concerning missed colonic lesions are multifactorial such as adequate bowel preparation, skill level of endoscopists, the number of endoscopy staff in the room as "eyes" to help with polyp detection and withdrawal time. following a pilot study in our endoscopy unit, we believe the size of the screen projecting the endoscopic image may have a positive influence on adenoma detection. therefore, we feel that a well-designed and adequately powered randomised controlled trial may help to confirm this.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or above * referred to the endoscopy unit for diagnostic or surveillance colonoscopy exclusion criteria: * familial history of familial adenomatous polyposis or hereditary non-polyposis colorectal cancer * known history of inflammatory bowel disease * emergency endoscopy of any nature (such as for gastrointestinal bleeding, assessment of large bowel investigation and colonic decompression) * patients with colostomy * previously incomplete colonoscopy (not including insufficient preparation) * patients with known palliative colorectal malignant disease patients with coagulopathies inability to give informed consent

Keywords: colonoscopy adenoma detection rate colorectal cancer screening screen size
a comparison study of the perclose proglide (tm) smc system versus figure-of-8- suture technique for closure of large-bore femoral venous access.

Conditions: Cardiovascular Diseases

Summary: this study aims to compare the efficacy and safety of two strategies for closing large caliber venous access in patients undergoing percutaneous procedures: compression with figure-of-8 suture versus closure with the perclose-proglide system.

this is a retrospective observational study that aims to compare two strategies for closing large-caliber femoral venous access in patients who have undergone percutaneous procedures. the study's goal is to determine if there are significant differences in terms of efficacy and safety between the two closure strategies. figure-of-8 suture compression is a well-established technique that has been used for decades to close large-bore femoral venous access, while the perclose-proglide system is a relatively new medical device that could have great utility for the closure of large-bore femoral venous access. by comparing these two strategies, researchers hope to determine the safety and effectiveness of the perclose-proglide system for closing large-bore femoral venous access in patients undergoing percutaneous procedures.

Eligibility criteria:
inclusion criteria: patients will meet all inclusion criteria: * adult patients aged \> 18 years * patients who have undergone percutaneous interventional procedures * patients in whom the procedures have been performed with femoral venous access * patients who have required large caliber pods ≥ 14 french. exclusion criteria: patients must not meet any exclusion criteria: * patients who have required access with surgical exposure. * patients who have required ipsilateral arterial access with a large caliber ≥ 14 french * patients with previous vascular surgery.

Keywords: femoral venous access closure techniques figure-of-8 suture,perclose-proglide system